Pacira | PCRX - Debt


Pacira reported $376.72M in Debt for its fiscal quarter ending in September of 2025.





Debt Change Date
Assertio Holdings USD 38.87M 615K Sep/2023
Astellas Pharma JPY 831.43B 83.94B Mar/2025
Bristol-Myers Squibb USD 51.04B 112M Sep/2025
Cara Therapeutics USD 0 0 Mar/2025
Coherus Biosciences USD 294.92M 1.25M Mar/2025
Heron Therapeutics USD 149.65M 157K Sep/2024
Ironwood Pharmaceuticals USD 583.99M 14.83M Dec/2024
J&J USD 45.8B 4.97B Sep/2025
Ligand Pharmaceuticals USD 451M 445.26M Sep/2025
Nektar Therapeutics USD 0 0 Jun/2022
Novo Nordisk DKK 118.72B 61.75B Mar/2025
Omeros USD 442.16M 199K Sep/2023
Pacira USD 376.72M 203.77M Sep/2025
Perrigo USD 3.64B 7.2M Sep/2025
Pfizer USD 60.85B 78M Sep/2025
Supernus Pharmaceuticals USD 42.21M 10.44M Sep/2025
Teva Pharmaceutical Industries USD 17.07B 450M Sep/2025
Xeris Pharmaceuticals USD 257.65M 431K Sep/2025
Xoma USD 120.79M 3.27M Jun/2024
Zoetis USD 7.27B 482M Sep/2025